{"id":15566,"date":"2026-06-03T21:54:00","date_gmt":"2026-06-03T19:54:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=93a083ff7b41dae31d70cb2d44bbb7a8"},"modified":"2026-06-03T21:54:00","modified_gmt":"2026-06-03T19:54:00","slug":"deadline-alert-zoetis-inc-zts-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=15566","title":{"rendered":"Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP<\/a> reminds investors of the upcoming July 27, 2026 <\/b>deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zoetis Inc. (\u201cZoetis\u201d or the \u201cCompany\u201d) (NYSE: ZTS<\/a>) securities between January 14, 2025 and May 6, 2026<\/b>, inclusive (the \u201cClass Period\u201d).<\/p><\/a><\/a>

\nIF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK <\/b>HERE<\/b><\/a> TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.<\/b><\/p>

\nWhat Happened?<\/b><\/p>

\nOn August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio.<\/p>

\nOn this news, Zoetis\u2019 stock price fell $5.69, or 3.8%, to close at $146.12 per share on August 5, 2025, thereby injuring investors.<\/p>

\nThen, on November 4, 2025, Zoetis released its third quarter 2025 financial results, revealing slowed growth across its key Companion Animal franchises and disclosing continued weakness in sales of its canine pain treatment, Librela, and increased competitive pressure in dermatology and parasiticides. The Company also lowered its full year sales outlook.<\/p>

\nOn this news, Zoetis\u2019 stock price fell $19.89, or 13.8%, to close at $124.46 per share on November 4, 2025.<\/p>

\nThen, on May 7, 2026, Zoetis released its first quarter 2026 financial results, reporting slowing overall revenue growth, declining Companion Animal sales performance, and worsening results across its key dermatology and parasiticides franchises, stating that \u201ccompetition intensified across key pet care categories, including dermatology and parasiticides,\u201d that \u201cpet owners demonstrated increased price sensitivity,\u201d and that \u201cthese new entrants have not yet translated into overall market expansion.\u201d<\/p>

\nThe Company also explained that \u201cprice has played a larger role in the decision process,\u201d that \u201c[s]hare loss is being amplified by a derm market with declining patient volume in the clinic,\u201d and that contraction in the parasiticides market was negatively impacting prescription volumes and compliance. In addition, the Company admitted that it was operating in \u201ca more price sensitive and competitive environment\u201d and further reduced its 2026 growth outlook based on continuing competitive and operating pressures.<\/p>

\nOn this news, Zoetis\u2019 stock price fell $23.91, or 21.5%, to close at $87.31 per share on May 7, 2026, thereby injuring investors further.<\/p>

\nWhat Is The Lawsuit About?<\/b><\/p>

\nThe complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis\u2019 Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis\u2019 Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis\u2019 dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis at all relevant times.<\/p>

\nIf you purchased or otherwise acquired Zoetis securities during the Class Period, you may move the Court no later than July 27, 2026 <\/b>to request appointment as lead plaintiff in this putative class action lawsuit.<\/p>

\nContact Us To Participate or Learn More:<\/b><\/p>

\nIf you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:\nCharles Linehan, Esq.,\nGlancy Prongay Wolke & Rotter LLP,\n1925 Century Park East, Suite 2100,\nLos Angeles California 90067\nEmail: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150,\nToll-Free: 888-773-9224\nVisit our website at www.glancylaw.com<\/a>.\nFollow us for updates on LinkedIn<\/a>, Twitter<\/a>, or Facebook<\/a>.<\/p>

\nIf you inquire by email, please include your mailing address, telephone number and number of shares purchased.<\/p>

\nTo be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

\nContact Us:<\/b>Glancy Prongay Wolke & Rotter LLP,\n1925 Century Park East, Suite 2100\nLos Angeles, CA 90067\nCharles Linehan<\/b>Email: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150\nToll-Free: 888-773-9224\nVisit our website at: www.glancylaw.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zoetis Inc…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15566","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15566"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15566\/revisions"}],"predecessor-version":[{"id":15567,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15566\/revisions\/15567"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}